title: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice.
abstract: The assessment of systemic lupus erythematosus (SLE) patients in routine clinical practice is mainly based on the experience of the treating physician. This carries the risk of unwanted variability. Variability may have an impact on the quality of care offered to SLE patients, thereby affecting outcomes. Recommendations represent systematically developed statements to help practitioners in reducing variability. However, major difficulties arise in the application of recommendations into clinical practice. In this respect, the use of quality indicators may raise the awareness among rheumatologists regarding potential deficiencies in services and improve the quality of health care. The aim of this study was to develop a set of quality indicators (QI) for SLE by translating into QIs the recently developed EULAR Recommendations for monitoring SLE patients in routine clinical practice and observational studies. Eleven QIs have been developed referring to the use of validated activity and damage indices in routine clinical practice, general evaluation of drug toxicity, evaluation of comorbidities, eye evaluation, laboratory assessment, evaluation of the presence of chronic viral infections, documentation of vaccination and of antibody testing at baseline. A disease specific set of quality assessment tools should help physicians deliver high quality of care across populations. Routine updates will be needed.
authors.affiliation: Rheumatology Unit, Department of Internal Medicine, University of Pisa, Italy. marta.mosca@int.med.unipi.it
authors.forename: M
authors.initials: M
authors.lastname: Mosca
authors.forename: C
authors.initials: C
authors.lastname: Tani
authors.forename: M
authors.initials: M
authors.lastname: Aringer
authors.forename: S
authors.initials: S
authors.lastname: Bombardieri
authors.forename: D
authors.initials: D
authors.lastname: Boumpas
authors.forename: R
authors.initials: R
authors.lastname: Cervera
authors.forename: A
authors.initials: A
authors.lastname: Doria
authors.forename: D
authors.initials: D
authors.lastname: Jayne
authors.forename: M A
authors.initials: MA
authors.lastname: Khamashta
authors.forename: A
authors.initials: A
authors.lastname: Kuhn
authors.forename: C
authors.initials: C
authors.lastname: Gordon
authors.forename: M
authors.initials: M
authors.lastname: Petri
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: R
authors.initials: R
authors.lastname: Talarico
authors.forename: A
authors.initials: A
authors.lastname: Tincani
authors.forename: M M
authors.initials: MM
authors.lastname: Ward
authors.forename: V P
authors.initials: VP
authors.lastname: Werth
authors.forename: L
authors.initials: L
authors.lastname: Carmona
mesh_terms: D058006:General Practice / Q000592:standards; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000628:therapy*; D011785:Quality Assurance, Health Care / Q000592:standards; D019984:Quality Indicators, Health Care / Q000592:standards*